Therefore, to be effective against the CNS phase of prion disease, these must be administered directly into the CNS of affected individuals, although use of camelid-derived PrP-specific heavy chain antibodies, or nanobodies, may offer an alternative approach [262]. Here, PRNP is linked to prion disease.